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Objective:  Malignant  transformation  of chronic  non-healing  wounds  is often  overlooked.  If a chronic
wound  fails  to heal,  or if there  are  changes  in  the  characteristics  of  a wound,  a biopsy  should  be performed.
Methods:  This  case  is  presented  in  line  with  SCARE  guidelines.
Presentation  of  case:  We  present  a case  of a man  with  a non-healing  traumatic  wound  over  two  years
in  which  a basal  cell  carcinoma  was  diagnosed  by  biopsy.  The  basal  cell  carcinoma  was radically  excisedeywords:
asal cell carcinoma
arjolin’s ulcer
hronic wounds
alignant ulcer
and  the  defect  was  closed  using  a split  thickness  skin  transplant.
Discussion:  The  term  Marjolin’s  ulcer,  pathophysiology  and  recommended  treatment.
Conclusion:  Delayed  diagnosis  of  malignancy  in chronic  wounds  can  lead  to  a  worsened  prognosis  and
therefore  it  is important  to exclude  a malignant  aetiology.  Malignant  transformation  of chronic  wounds
is not  common  but Marjolin’s  ulcer  should  be considered.
©  2018  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
 articaccess
. Introduction
Basal cell carcinoma (BCC) is the most common non-melanoma
NMM)  skin cancer [1]. BCCs seldom metastasize, but can be locally
nvasive [2]. BCCs are suspected during clinical examination with
he use of dermatoscopy of the lesion and diagnosis is conﬁrmed
istologically. The pathogenesis of BCC is multifactorial. Risk factors
nclude exposure to ultraviolet light, ionizing radiation, chemicals
uch as arsenic, immunosuppression and phenotypical factors, for
xample light skin, light and red hair colour and light eye colour.
enetic factors also play a role [1].
Trauma has also been suggested as a risk factor in the devel-
pment of basal cell carcinomas [3,4]. Malignant degeneration of
ounds and scars is a well-accepted concept, but the pathophys-
ology has been much debated. The earliest reports were noted
y Celcus in the 1th century in burn scars [5]. Jean-Nicholas Mar-
olin described ulceration within a burn wound in 1828. In 1850
obert Smith described the malignant nature of the pathology Jean-
icholas Marjolin had reported and called it Marjolin’s ulcer (MU).
he term MU is most often used when referring to burn scar wounds
nd squamous cell carcinomas (SCC) [6]. Other types of carcinomas,
or example BCC, sarcoma and melanoma, arising in scars/chronic
ounds have been called scar tissue carcinomas [7]. The term MU
s however often used to describe malignancy that arises in chronic
ounds and cutaneous scars.
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210-2612/© 2018 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group
rg/licenses/by/4.0/).le under  the  CC  BY license  (http://creativecommons.org/licenses/by/4.0/).
We  present a case of a 73-year-old man  with a history of a non-
healing wound in which a BCC is diagnosed. The patient was  treated
at the Department of Plastic Surgery and Breast Surgery, Zealand
University Hospital, Roskilde, Denmark. This case highlights the
importance of considering and excluding malignancy in a chronic
wound. The work has been reported in line with SCARE guidelines
[8].
2. Case report
A 71-year-old man, known with polycythemia vera and aortas-
tenosis, sustained a wound laterally on his right mid lower leg when
he fell and struck a hospital bed, which failed to heal over a 2-year
period. The patient was referred 2 years post trauma to a wound
centre as the wound had failed to heal after 6 months of treatment
by his General Practitioner.
At the wound centre the patient received treatment for a non-
healing ulcer by means of various ointments, honey and dressings,
with a view to referral for skin transplantation if the wound did
not heal satisfactorily. It is noted that the patient was  not diabetic
and did not have any cardiovascular risk factors but was under-
going follow-up for aortastenosis and polycythemia vera. There
was initially improvement in the wound over an approximately
six-month period, but due to the return of hypergranulation tis-
sue, increasing size of the wound and a request from the patient, a
punch biopsy of the wound was  taken which conﬁrmed basal cell
carcinoma. The patient was referred to The Department of Plastic
Surgery and Breast Surgery, Roskilde Hospital for excision of the
carcinoma. The ulcer, approximately 4 cm in diameter (Fig. 1), was
 Ltd. This is an open access article under the CC BY license (http://creativecommons.
CASE  REPORT  –  O
D.-L. Day et al. / International Journal of Sur
F
s
s
t
w
t
r
S
p
t
r
w
d
3
b
w
c
s
e
M
f
[
a
c
s
c
o
i
s
r
a
y
D
d
c
t
f
w
f
i
t
aig. 1. Non-healing wound on the right lower limb approximately 4 cm in diameter.
urgically excised with a 5 mm margin, without the use of frozen
ections, and covered with a split thickness skin transplant. The his-
ology showed an ulcerated basal cell carcinoma of nodular type,
ith growth deep into the dermis, but not involving the subcu-
aneous tissue. Histology also showed that the BCC was  radically
emoved. Post-operative control included follow up in the Plastic
urgery clinic for approximately one month. After the skin trans-
lant healed the patient was discharged from follow up in our clinic
o yearly control at his Dermatologist. There has been no local
ecurrence of the BCC. The patient was subsequently diagnosed,
ith diabetes mellitus type two (DMT2) and started treatment with
ietary changes and exercise.
. Discussion
MU are reported as arising within about 2% of all burn scars
ut are also described within surgical scars and chronic wounds
ith varying aetiologies. Traumatic wounds, diabetic wounds and
hronic venous ulcer wounds have also been reported [9].
MU most commonly refer to SCC, however, BCC, melanoma and
arcoma have also been described. In a literature review by Kowal
t al [10] 71% of MUs  were SCC, 12% BCC and 6% melanoma.
In the literature MUs  are described as either chronic or acute.
ost cases reported are chronic with an average latency period
rom time of injury to malignant transformation of about 32 years
10]. Acute MUs  arise within 12 months. There is however a debate
bout acute MU.  Some authors argue that the presence of skin can-
er within an acute wound could be coincidental. Other authors
tate that the injury accelerates an already present process of car-
inogenesis. It is not clear from the literature if there is histological
r prognostic difference between acute and chronic MU [11]. What
s clear is that changes in wound character or chronicity of a wound
hould lead to a biopsy. In an article by Bazalinksi et al. [12] it is
eported that SCC are more common in chronic MU and BCC in
cute MU.
The patient in our case was diagnosed with BCC around two
ears after trauma. Furthermore, the patient was  diagnosed with
MT2 after surgery. It is known that patients with DMT2 have
elayed wound healing. These patients are at risk for developing
hronic ulcers, which is thought to be a risk factor for malignant
ransformation [11]. DMT2 has been showed to be a risk factor
or certain types of cancer and has been linked in the literature
ith non-melanoma skin cancer [13]. There is however no evidenceor a causal link. It must also be noted that the patient presented
n this case is known with Polycythemia Vera. In 2012 he began
reatment with Ruxolitinib, a Janus-associated kinase inhibitor. In
 study by Blecham et al. [14] patients who have received Ruxoli-PEN  ACCESS
gery Case Reports 53 (2018) 468–470 469
tinib are reported to develop aggressive skin cancers, including BCC
and SCC. Willkens et al. [15] also describe the development of BCC
in a patient treated with Ruxolitinib but do not ascribe a causal link.
Further research needds to be done to determine a causal link. In our
case there are multiple factors that could potentially have caused
the onset of carcinogenesis. In the literature the pathogenesis of
MU is unknown, however multiple theories have been postulated
[11]. These include:
1 toxin theory in which tissue damage leads to the release of toxins
which can cause cell mutation
2 chronic irritation theory where by chronic irritation induces car-
cinogenesis
3 injury stimulates latent malignant cells within the wound
4 the avascular nature of scar tissue allows unchecked tumor
growth
5 a genetic theory involving the p53 gene, HLA DLA and FAS genes.
The recommended treatment of MU is wide local excision and
lymph node dissection. Most cases describe recommendations for
MU of SCC type. The term MU covers a variety of cancers and there is
need for further research so that treatment recommendations can
be given for the various tumors found in scars and chronic non-
healing wounds.
4. Conclusion
We have presented a patient in whom a non-healing traumatic
wound masks a BCC. It is essential to be aware of the multifactorial
nature of chronic wounds and this case highlights the importance of
excluding malignancy in all non-healing wounds. Wounds that are
chronic or change in characteristic should be biopsied to exclude
malignancy.
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